Autoimmune haemolytic anaemia (AIHA) presents a complex clinical picture where the immune system mistakenly targets the body’s own red blood cells for destruction. This misguided attack reduces the circulating red blood cell count, leading to fatigue, weakness, and pallor as the blood’s oxygen-carrying capacity diminishes. Understanding the underlying triggers and mechanisms is essential for accurate diagnosis and effective management, as the condition can range from mild and chronic to severe and life-threatening.
Primary and Secondary Triggers
The search for autoimmune haemolytic anaemia causes often begins by categorising the condition as either primary or secondary. In primary AIHA, the immune system produces antibodies, typically immunoglobulin G (IgG) or immunoglobulin M (IgM), that act against red blood cells without an identifiable underlying disorder. Conversely, secondary AIHA occurs as a manifestation of another systemic disease, where the production of these harmful antibodies is a consequence of an existing pathological process.
Autoimmune Disorders and Lymphoproliferation
Several systemic autoimmune diseases are well-documented contributors to secondary AIHA, highlighting the interconnected nature of immune dysregulation. Conditions such as systemic lupus erythematosus frequently involve the production of autoantibodies that cross-react with red blood cell surfaces. Other autoimmune haemolytic anaemia causes include rheumatoid arthritis, Sjögren's syndrome, and systemic sclerosis, where chronic inflammation creates an environment conducive to the production of erythrocyte-targeting antibodies.
Lymphoproliferative disorders represent another significant category of underlying causes. Chronic lymphocytic leukaemia (CLL) is the most common haematological malignancy associated with AIHA, where the malignant B-cells can aberrantly produce autoantibodies. Non-Hodgkin lymphomas and other B-cell disorders may also trigger this immune-mediated destruction, often complicating the clinical picture of the primary cancer.
Medication-Induced Immune Activation
A considerable proportion of AIHA cases are linked to specific pharmacological agents, classifying them as drug-induced immune haemolytic anaemias. Certain antibiotics, particularly penicillins and cephalosporins, can bind to red blood cell membranes, transforming them into targets for immune attack once the drug is cleared. This reaction is usually reversible upon discontinuation of the medication.
Other drugs, such as methyldopa, levodopa, and certain non-steroidal anti-inflammatory drugs (NSAIDs), can induce the production of true autoantibodies that persist beyond the duration of drug therapy. Recognising these medication-induced causes is a critical step in managing the condition, as identifying the trigger can lead to resolution without the need for aggressive immunosuppression.
Infectious Agents and Molecular Mimicry
Various infectious pathogens have been implicated in the onset of autoimmune haemolytic anaemia causes through mechanisms such as molecular mimicry, where foreign antigens on the microbe closely resemble the body's own red blood cell proteins. Viral infections, including Mycoplasma pneumoniae, cytomegalovirus (CMV), and Epstein-Barr virus (EBV), are frequently associated with acute-onset AIHA. Bacterial infections, such as those caused by Clostridium species, can also provoke this immune response.
Clinical Assessment and Diagnostic Strategy
Determining the specific autoimmune haemolytic anaemia causes in an individual patient requires a thorough and systematic diagnostic approach. A comprehensive medical history focusing on recent infections, medication use, and symptoms of underlying systemic disease is the cornerstone of the initial assessment. This is followed by targeted laboratory investigations, including a direct antiglobulin test (DAT) to identify the presence of antibodies or complement on red blood cells, and a detailed haematological workup to characterise the anaemia.
Identifying the root cause is not merely an academic exercise; it directly influences therapeutic decisions. For instance, stopping an offending drug or treating an underlying infection may resolve the anaemia, whereas a primary autoimmune or lymphoproliferative disorder may require more intensive immunosuppressive therapy to control the pathological antibody production.
